Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Persistent Atrial Fibrillation with Sphere-9 Catheter and Affera Mapping and Ablation System

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Symptomatic PerAF documented by (1) a physician's note indicating symptoms consistent with AF sustained longer than 7 days but less than 12 months; AND either (2a) a 24-hour Holter documenting continuous AF within the past year OR (2b) two electrocardiograms (from any form of rhythm monitoring, including consumer devices) taken at least 7 days apart within the past year, each showing continuous AF.~2. Failure or intolerance of at least one Class I or III anti-arrhythmic drug (AAD).~3. Suitable candidate for catheter ablation.~4. Adults aged 18 - 80 years.~5. Willing and able to comply with all baseline and follow-up evaluations for the full length of the study.~6. Willing and able to provide informed consent.~Exclusion Criteria:~1. Continuous AF lasting for 12 months or longer.~2. AF secondary to electrolyte imbalance, thyroid disease, acute alcohol intoxication, or other reversible or non-cardiac cause.~3. Previous left atrial ablation or surgical procedure (including septal closure or left atrial appendage closure).~4. Valvular cardiac surgical/percutaneous procedure (e.g., ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve).~5. Any carotid stenting or endarterectomy.~6. Any cardiac procedure (surgical or percutaneous) or percutaneous coronary intervention within the 90 days prior to the initial procedure.~7. Coronary artery bypass graft (CABG) procedure within the 6 months prior to the initial procedure.~8. Awaiting cardiac transplantation or other cardiac surgery within the 12 months following the initial ablation procedure.~9. Presence of a permanent pacemaker, biventricular pacemaker, or any type of implantable cardiac defibrillator (with or without biventricular pacing function).~10. Documented thromboembolic event (stroke or transient ischemic attack) within 6 months (180 days) prior to the initial ablation procedure.~11. Documented left atrial thrombus on imaging.~12. History of blood clotting or bleeding abnormalities.~13. Any condition contraindicating chronic anticoagulation.~14. Myocardial infarction (MI) within the 3 months (90 days) prior to the initial procedure.~15. Body mass index \>40 kg/m2.~16. Left atrial diameter \>55 mm (anterioposterior).~17. Diagnosed atrial myxoma.~18. Left ventricular ejection fraction (EF) \< 35%.~19. Uncontrolled heart failure or NYHA Class III or IV heart failure.~20. Rheumatic heart disease.~21. Hypertrophic cardiomyopathy.~22. Unstable angina.~23. Moderate to severe mitral valve stenosis.~24. Severe mitral regurgitation (regurgitant volume ≥ 60 mL/beat, regurgitant fraction ≥ 50%, and/or effective regurgitant orifice area ≥ 0.40cm2).~25. Primary pulmonary hypertension.~26. Significant restrictive or obstructive pulmonary disease or chronic respiratory condition.~27. Renal failure requiring dialysis.~28. History of severe Gastroesophageal Reflux Disease (GERD) requiring surgical and/or mechanical intervention.~29. Acute illness, active systemic infection, or sepsis.~30. Contraindication to both computed tomography and magnetic resonance angiography.~31. Significant congenital anomaly or medical problem that, in the opinion of the investigator, would preclude enrollment in this study or compliance with follow-up requirements or would impact the scientific soundness of the clinical study results.~32. Any woman known to be pregnant or breastfeeding, or any woman of childbearing potential who is not on a reliable form of birth regulation method or abstinence.~33. Current or anticipated participation in any other clinical study of a drug, device, or biologic during the duration of the study not pre-approved by the Sponsor.~34. Presence of intramural thrombus, tumor, or other abnormality that precludes vascular access, catheter introduction, or manipulation.~35. Known drug or alcohol dependency.~36. Life expectancy less than 12 months.~37. Vulnerable subject (such as a prisoner or handicapped or mentally disabled person).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Sphere-9 Catheter (Type: EXPERIMENTAL): Sphere-9™ Mapping and Ablation Catheter; Affera Mapping System; Affera Ablation System
- THERMOCOOL SMARTTOUCH SF (Type: ACTIVE_COMPARATOR): THERMOCOOL SMARTTOUCH® SF Catheter; SMARTABLATE® System; CARTO® 3 System

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete